Trial Profile
A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Olaptesed pegol (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Keynote-559; OPERA
- Sponsors NOXXON Pharma AG
- 17 Mar 2023 According to Genentech media release, company will present abstract from this study.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 17 Sep 2020 According to a NOXXON Pharma AG media release,The poster presentation is complemented by a video presentation with remarks highlighting the trial's most significant data provided by Dr. Niels Halama from the National Center for Tumor Diseases (NCT) in Heidelberg, Germany, the first author of the poster presentation and the principal investigator of the trial.